2017 Conference Access Set (Plenaries, Symposia & Workshops)


Standard: Free

Products

DG17: NTR: Partnerships in Care & Nutrition Education: Thinking Outside the Box

Preview Available

DG17: NTR: Partnerships in Care & Nutrition Education: Thinking Outside the Box

Nov 3, 2017 4:00pm ‐ Nov 3, 2017 6:00pm

Patient/provider panels will discuss the partnering process among CF patients, families, and providers for sustaining daily CF care to achieve realistic and mutually acceptable nutrition goals through collaboration and education.

Learning Objectives:

  1. Compare and contrast divergent goals from provider and patient/family viewpoints to promote optimal nutrition therapy,
  2. Employ strategies to improve patient/family adherence to mutually agreed upon treatment plans,
  3. Identify and utilize a variety of resources within the online CF community for positive nutrition messaging for CF patients and families.

Discipline Group Sessions Chair(s): Discipline Group Sessions Speaker(s):

P1: Matching Medicines With Mutations

Preview Available

P1: Matching Medicines With Mutations

Nov 2, 2017 4:30pm ‐ Nov 2, 2017 6:00pm

Increasing numbers of people with CF now benefit from disease-altering small molecule therapies that target the basic defect in CFTR. Use of these therapies has been extended recently using a combination of in vitro laboratory experiments to identify responsive mutations, and clinical trials to determine effect on clinical outcomes. This plenary will summarize how recent advances may allow in the near future over 90% of individuals with CF to benefit from therapies that target the basic defect in CFTR, including even those with the rarest disease causing mutations.

Learning Objectives:

  1. Define that although CF is caused by a number of different mechanisms, mutations can be grouped by the nature of the defect and responsiveness to small molecule therapeutics.
  2. Recall how laboratory experiments can and are being used to determine which rare disease-causing mutations are responsive to therapies.
  3. Recall how recent advances may allow in the near future over 90% of individuals with CF to benefit from therapies that target the basic defect in CFTR.

Plenary Leader(s): Speaker(s):

P2: Lung Transplantation: Challenges & Opportunities for Advanced CF Lung Disease

Preview Available

P2: Lung Transplantation: Challenges & Opportunities for Advanced CF Lung Disease

Nov 3, 2017 9:00am ‐ Nov 3, 2017 10:00am

Plenary 2 will review the progression of CF lung disease and the option of lung transplant to treat advanced disease. The presentation will highlight the challenges associated with each phase of the transplant journey, including the referral to a transplant center, waiting for a transplant, undergoing the transplant procedure, and the care requirements and life after transplant.

Learning Objectives:

  1. Discuss the progression of CF lung disease and the difficulties in predicting survival.
  2. Apply knowledge of lung transplant outcomes and the referral process to inform the lung transplant discussion with patients and families.
  3. Use an understanding of challenges before and after transplant to support patients and families through the process and work with transplant centers to optimize transplant outcomes.

Plenary Leader(s): Speaker(s):

P3: Partnering With the Community

Preview Available

P3: Partnering With the Community

Nov 4, 2017 9:00am ‐ Nov 4, 2017 10:00am

This plenary session will focus on ways people with CF and their families make a difference by partnering with the larger community as advocates, by sharing their expertise on living life with CF with their care center teams, and by supporting with each other through virtual events and peer mentoring.

Learning Objectives:

  1. Identify ways that people with CF and their families have affected change through advocacy.
  2. Explain how shared humanity and shared expertise can enhance care center visits.
  3. Describe new programs to allow adults with CF to connect with each other.

Plenary Leader(s):
  • Drucy Borowitz, M.D., Vice President, Community Partnerships, Cystic Fibrosis Foundation
  • Mary B. Dwight, B.A., Senior Vice President for Policy & Advocacy
Plenary Panelist(s): Speaker(s):
  • Cynthia George, R.N., M.S.N., F.N.P., Sr. Director Partnerships for Sustaining Daily Care

S01: CFTR: Orbiting the Atomic Structure

Preview Available

S01: CFTR: Orbiting the Atomic Structure

Nov 2, 2017 2:00pm ‐ Nov 2, 2017 3:25pm

The recently solved structures of full-length CFTR provide a template on which to evaluate electrophysiological and biochemical studies of this channel forming membrane protein. This symposium will discuss the cryo-electron microscopy structures of CFTR and their use for the interpretation of channel function studies and disease-causing mutations. Additionally, the symposium will explore the application of these structures for the development of new therapeutics for common and rare CF-causing alleles.

Learning Objectives:

  1. Examine the current structural and functional data to explore CFTR channel function.
  2. Apply the existing structural and functional data to understand the molecular defects caused by CF-associated mutations.
  3. Assess how structural and functional studies can be leveraged for future therapeutic development.

Symposium Chair(s): Symposium Speaker(s):

S02: CLIN: Caroline McPherson Symposium: Pulmonary Guidelines & Current Practice Updates in Treatments of CF Lung Disease

Preview Available

S02: CLIN: Caroline McPherson Symposium: Pulmonary Guidelines & Current Practice Updates in Treatments of CF Lung Disease

Nov 2, 2017 2:00pm ‐ Nov 2, 2017 3:25pm

This session will review guidelines for CF therapy, the implementation of guidelines into clinical practice, assessment of CF lung disease, and challenges in the treatment of advanced CF lung disease.

Learning Objectives:

  1. Define the recommendations for the use of CFTR modulators in the treatment of CF.
  2. Describe the management of patients with severe CF lung disease including the variation in inpatient treatment of CF pulmonary exacerbations and factors important in decisions to refer for lung transplant.
  3. Define the status of multiple breath washout as a tool to guide clinical management of CF lung disease.

Symposium Chair(s): Symposium Speaker(s):

S03: GMS: CF Animal Models: Choosing the Right Tool for the Job

Preview Available

S03: GMS: CF Animal Models: Choosing the Right Tool for the Job

Nov 2, 2017 2:00pm ‐ Nov 2, 2017 3:25pm

This session will focus on the utilization of CF animal models for investigation into CF disease manifestations of diabetes, airway clearance, altered intestinal stem cell proliferation and gastrointestinal cancer risk. Studies of CF ferrets, pigs, mice and ex vivo applications (cell or organoid culture) investigate the specific roles of CFTR in beta cell function, mucociliary clearance of the airways, Wnt signaling of stem cells and intestinal tumor suppression. These topics are discussed within the context of the utility and limitations of these animal models for understanding CF disease and its treatment.

Learning Objectives:

  1. Explain the utility of the CF ferret model in understanding the ways that CFTR affects the biology of pancreatic beta cells and its relevance to the major co-morbidity CF-related diabetes.
  2. Describe the utility and limitations of the CF pig model for recapitulating CF airway disease and the outcomes that might alter current treatment of failed airway clearance.
  3. Discuss the contributions and limitations of the CF mouse model for understanding intestinal hyperproliferation and the increased risk of gastrointestinal cancer in CF patients.

Symposium Chair(s): Symposium Speaker(s):

S04: INF/MIC: Antimicrobial Agents: What's New?

Preview Available

S04: INF/MIC: Antimicrobial Agents: What's New?

Nov 2, 2017 2:00pm ‐ Nov 2, 2017 3:25pm

This session will review currently available new antibiotics as well as drugs and compounds currently under development for the treatment of pulmonary infections in individuals with cystic fibrosis.

Learning Objectives:

  1. Describe the antibiotics used in novel ways as well as newly available antibiotics in the treatment of pulmonary infections.
  2. Discuss development and early clinical trials of gallium as an antimicrobial in CF patients.
  3. Examine the mechanism of action and development of antimicrobial peptides as a therapeutic agent for individuals with CF.

Symposium Chair(s): Symposium Speaker(s):

S05: NTR-CLIN: Multidisciplinary Approach to Nutrition

Preview Available

S05: NTR-CLIN: Multidisciplinary Approach to Nutrition

Nov 2, 2017 2:00pm ‐ Nov 2, 2017 3:25pm

An interactive session designed to review the role of various services important in contributing to the nutritional management of individuals with cystic fibrosis and how these services are integrated to provide optimal care.

Learning Objectives:

  1. Review the role of various services in their contribution to the nutritional management of individuals with cystic fibrosis.
  2. Describe how specific centers integrate these services to provide nutritional care.
  3. Discuss goals for establishing future innovative ways to integrate these services.

Symposium Chair(s): Symposium Speaker(s):

S06: PT&RT: Airway Physiology for Airway Clearance: Lessons for the Clinician

Preview Available

S06: PT&RT: Airway Physiology for Airway Clearance: Lessons for the Clinician

Nov 2, 2017 2:00pm ‐ Nov 2, 2017 3:25pm

This symposium is designed to promote discussion of airway clearance techniques for people with cystic fibrosis based on airway physiology and methods of choice. The first talk begins with an overview of lung physiology and mucociliary clearance, followed by a discussion of airway clearance techniques that do not require a device, such as percussion and vibration, active cycle of breathing techniques, autogenic drainage, and exercise. We will then discuss airway clearance techniques that require a device, such as PEP, Oscillating PEP, HFCWO/HFCC, and IPV. The final talk will discuss personalizing airway clearance techniques for people with cystic fibrosis based on their lung pathology.

Learning Objectives:

  1. Discuss lung physiology as it relates to mucociliary clearance in people with CF.
  2. Discuss the underlying physiological mechanism of action for ACTs.
  3. Discuss personalizing ACTs based on the person with CF's lung pathology and the ACTs mode of action.

Symposium Chair(s): Symposium Speaker(s):